Table 3.
Sampling timepoints and adverse reaction profiles of inactivated COVID-19 vaccine.
| Vaccination Characteristic | Corona Vac (n = 133) | BBIBP-CorV (n = 99) | P-value |
|---|---|---|---|
| Pregnancy status | / | ||
| Periconception | 100 | 73 | |
| Pregnant at time of vaccination | 33 | 26 | |
| Gestational age at second vaccine dose | / | ||
| <2 weeks | 100 | 73 | |
| 2-6 weeks | 31 | 25 | |
| 6-12 weeks | 2 | 1 | |
| Timepoints for blood collection after second dose | / | ||
| ≤12 weeks | 53 | 39 | |
| 12-24 weeks | 22 | 18 | |
| Seroconversion rate | |||
| Time from COVID-19 vaccination at the second dose to blood sampling ≤12 weeks | 62.3% (33/53) | 41% (16/39) | <0.0001 |
| Time from COVID-19 vaccination at the second dose to blood sampling at 12-24 weeks | 45.5% (10/22) | 0% (0/18) | 10.91 |
| The geometric mean titer of neutralizing antibodies | |||
| Time from COVID-19 vaccination at the second dose to blood sampling ≤12 weeks | 5.63 | 3.16 | 0.02 |
| Time from COVID-19 vaccination at the second dose to blood sampling at 12-24 weeks | 3.09 | 2.09 | 0.07 |
| Side effects of vaccine | |||
| Injection site soreness | 9.8% (13/133) | 10.1% (10/99) | 0.93 |
| Injection site reaction or rash | 12% (16/133) | 13.1% (13/99) | 0.80 |
| Headache | 3.8% (5/133) | 4.0% (4/99) | 0.91 |
| Fatigue | 8.3% (11/133) | 8.1% (8/99) | 0.96 |
| Fever or chills | 3.8% (5/133) | 3% (3/99) | 0.76 |
| Allergic reaction | 0.8% (1/133) | 0 | 0.75 |